Welcome to our dedicated page for SenesTech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on SenesTech stock.
SenesTech, Inc. develops and commercializes fertility-control products for managing animal pest populations, with current products focused on rat and mouse populations. Its product names include ContraPest, Evolve Rat, and Evolve Mouse, which are used within pest-management programs as alternatives or complements to traditional rodent-control methods.
Company news centers on Evolve commercialization, e-commerce and direct-to-consumer sales channels, Amazon marketplace management, field-study data on rodent activity, product approvals in international markets, quarterly and annual financial results, capital runway commentary, and executive leadership or board governance updates.
SenesTech (NASDAQ: SNES) reported that Q3 2021 revenues exceeded $183,000, more than doubling from $77,000 in Q3 2020. Year-to-date revenues also more than doubled, driven by growth in agribusiness, municipalities, and direct-to-consumer markets. The company added around 350 new customers, with California sales accounting for nearly 30% of total sales. Despite revenue growth, Q3 net loss widened to $(2.3) million from $(1.9) million in Q3 2020. As of September, the company had $11.1 million in cash to support further growth initiatives.
SenesTech, Inc. (NASDAQ: SNES) will report its financial results for Q3 2021 after market close on November 10, 2021. A conference call is scheduled for the same day at 5:00 pm ET to discuss the results. SenesTech focuses on managing pest populations through its proprietary fertility control technology, ContraPest®, which is the first EPA registered rodent contraceptive. This initiative aims to significantly reduce rodent populations and promote a healthier environment.
SenesTech (NASDAQ: SNES) has seen municipalities across the U.S. increasingly adopt its rat contraceptive, ContraPest®, with Newton, Massachusetts, now joining cities like Washington DC and San Francisco. ContraPest® is the only EPA-approved rat birth control, demonstrating over 94% efficacy in reducing rat populations. Sales revenues for ContraPest® soared over 100% in 2021, primarily driven by California's implementation of rodenticide restrictions. This innovative solution addresses the growing rat problem exacerbated by the pandemic, aiming for sustainable pest control without harmful impacts.
SenesTech, Inc. (NASDAQ: SNES) has announced its participation in the Lytham Partners Fall 2021 Investor Conference on October 7, 2021 at 3:30 PM ET. The event will be accessible via a webcast on the company's website, with an archived replay available post-event. Management will also hold virtual one-on-one meetings during the conference from October 5 to 7. As a leader in fertility control technology for pest management, SenesTech aims to promote a healthier environment through its proprietary product, ContraPest, the first U.S. EPA registered rodent contraceptive.
SenesTech, Inc. (NASDAQ: SNES) reported a 125% revenue increase in Q2 2021 compared to Q2 2020, totaling $160,000. Year-to-date revenues rose 130%. Growth is fueled by the adoption of ContraPest, especially in California, following legislation limiting anticoagulant rodenticides. The company engages nearly 500 active customers, with 250 new additions in Q2. Despite a net loss of $(1.7) million, cash reserves stand at $13.1 million. An aggressive marketing campaign, "Operation Rat Race," is set to further boost sales.
SenesTech, Inc. (NASDAQ: SNES) will report its second quarter 2021 financial results on August 12, 2021, after market close. The company specializes in fertility control technologies for managing animal pest populations, particularly rats, through its proprietary product, ContraPest. A conference call to discuss the results is scheduled for 5:00 pm ET on the same day, accessible via phone or live webcast. Interested parties can engage in the call through specified dial-in numbers or the investor relations section of their website.
SenesTech, Inc. (NASDAQ: SNES) announced its participation in the Lytham Partners Spring 2021 Investor Conference, scheduled for June 15, 2021, at 11:45 AM ET. A webcast of the presentation will be available on their website, along with virtual one-on-one meetings from June 14-16, 2021. SenesTech specializes in innovative pest management through its proprietary technology, ContraPest®, aimed at controlling rat populations by targeting reproduction. This approach is considered low hazard for non-target species. For more information, visit senestech.com.
SenesTech, Inc. (NASDAQ: SNES) reported a 138% increase in Q1 2021 revenues to approximately $88,000 year-on-year, with operating expenses reduced by 20%. The company, specializing in rodent fertility control, experienced significant traction in California due to legislation prohibiting certain rodenticides. Cash reserves stand at $15.2 million, supporting future growth. Notable successes included significant population reductions of rats observed in agricultural settings. The firm has transitioned to a solutions-based model and rebranded itself as 'The Pest Control Difference.'
SenesTech, Inc. (NASDAQ: SNES), known for its innovative fertility control solutions for pest management, will release its financial results for the first quarter of 2021 on May 13, 2021, after market close. A conference call to discuss the results is scheduled for the same day at 5:00 pm ET. The company emphasizes its commitment to revolutionizing pest control through its proprietary technology, ContraPest®, which targets reproduction in rat populations. This approach aims to reduce reliance on lethal pest management methods.
SenesTech (NASDAQ: SNES) has launched a new brand campaign, "The Pest Control Difference," highlighting its revolutionary ContraPest® product aimed at managing rodent populations through fertility control. The rebrand signifies the company's transition to a solutions-oriented, environmentally responsible entity within pest management. ContraPest®, proven effective in reducing rat populations non-lethally, is now available for use across all 50 states. Key initiatives include partnerships with distributors and a new loyalty program.